BRAINTREE, Mass.--(BUSINESS WIRE)--Paragonix Technologies, Inc. will present the SherpaPak™ Organ Transport product line at Booth 128 during the Annual American Transplant Congress (ATC) held at the McCormick Place – Lakeside Center in Chicago, April 29 - May 3, 2017. The SherpaPak™ Organ Transport product line1,2 combines innovative cooling technology with safe, consistent methods for cold ischemic storage and transport of donor organs to recipients for implantation.
During the recent 37th Annual Meeting of the International Society for Heart and Lung Transplantation (ISHLT) held in San Diego, Sebastian G.A. Michel, MD3 presented preclinical results for the SherpaPerfusion™ Cardiac Transport System4,5 “12 hour hypothermic oxygenated machine perfusion preserves the quality of donor hearts: a biomarker analysis.” The SherpaPerfusion™ Cardiac Transport System is designed to improve donor heart quality during currently accepted clinical preservation intervals and to extend preservation times. Dr. Michel, lead author commented, “We were excited to present biomarker data gathered on porcine hearts preserved using SherpaPerfusion™ Cardiac Transport System for 12 hour transportation intervals.”
Dr. Lisa Anderson, President and COO, for Paragonix commented, “We are looking forward to discussing the SherpaPak™ Organ Transport Systems with the clinical community during the ATC. ”
Paragonix previously announced March 27, 2017 Presentation of the SherpaPak™ Organ Transport Systems and SherpaPerfusion™ Cardiac Transport System at the 37th Annual Meeting of the International Society for Heart and Lung Transplantation (San Diego, 5 – 8 April 2017)
Paragonix previously announced February 7, 2017 an exclusive distribution agreement with MBA Medical to market Paragonix Technologies’ SherpaPak™ Cardiac and Kidney Transport Systems, in the Southern United States.
Paragonix previously announced January 9, 2017 a Presentation of the SherpaPak™ Organ Transport Systems during the ASTS 17th Annual State of the Art Winter Symposium January 26 to 29, 2017 in Miami, FL
Paragonix previously announced January 4, 2017 an exclusive supply agreement with Sanbor Medical for the Manufacture and Assembly of SherpaPak™ Organ Transport Systems
Paragonix previously announced December 22, 2016 an exclusive distribution agreement with Bio Instruments for Paragonix SherpaPak™ Cardiac and Kidney Transport Systems in the Midwestern United States
Paragonix previously announced November 9, 2016 an exclusive distribution agreement with Pacific West Medical Sales for Paragonix SherpaPak™ Cardiac and Kidney Transport Systems in California
About the American Transplant Congress
The American Transplant Congress (ATC) is the joint annual Congress of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST). ATC provides a forum for exchange of new scientific and clinical information relevant to solid organ and tissue transplantation and brings together transplant physicians, scientists, nurses, organ procurement personnel, pharmacists, allied health professionals, and other transplant professionals. The educational offerings provide attendees the opportunity to learn cutting-edge advances in research and promotes the exchange of ideas and practice in the field of solid organ and tissue transplantation.
About the Paragonix SherpaPak™ and SherpaPerfusion™ Cardiac Transport
Currently, the availability of cardiac transplantation is governed by the “ischemic time”, that being, the elapsed time from heart donation to recipient implantation. According to The International Society Of Heart and Lung Transplantation (“ISHLT”) guidelines6 for the care of heart transplant recipients, the projected ischemic time should not exceed 4 hours7,8, limiting the distance available to transport a donor heart. Paragonix SherpaPak™ Cardiac Transport System is fully disposable, eliminating problems associated with maintenance, device transport and contamination. The Paragonix SherpaPerfusion™ Cardiac Transport System combines innovative oxygenated perfusion of organs and safe organ storage with the ultimate goal of extending ischemic time to 12 hours, significantly altering the transportation range of donor hearts.
About the Cardiac Transplantation Market
Cardiac transplantation is considered the gold standard therapy for patients in end-stage heart failure.9 With over 5.8 million Americans currently diagnosed with heart failure (HF), growing at an annual rate of 400,000 per year10, there is a persistent need to provide end-stage heart failure support to this expanding population. Estimates of the prevalence of symptomatic HF in the general European population are similar to those in the United States.11 The annual economic burden of treating heart failure exceeds $34.4 billion12, over 50% of which is due to the cost of hospitalization.13 The financial demands associated with transplantation are considerable. The estimated first year costs for heart transplant are $997,700, and subsequent annual costs can easily exceed $30,00014. In the United States, around 30,000 people die annually from end-stage heart disease. As of June 1, 2012, 3,203 patients in the United States are on the waiting list for a heart transplant15. Based on 2011 data, just over 2,300 patients will receive a live-saving transplant each year, which is reflective of the enormous donor heart shortage. These data, however, only seem to represent the tip of the iceberg. Assuming that up to 50,000 people with end-stage heart failure are candidates for transplantation16, maximization of donor organ utilization has enormous potential in cardiac transplantation.
About Paragonix Technologies, Inc.
Based in Massachusetts and founded in 2010, Paragonix Technologies Inc., is a privately held medical device company innovating the Paragonix SherpaPak™ and SherpaPerfusion™ Cardiac Transport System, a novel, single-use organ preservation device to improve donor organ quality. Paragonix has established a pipeline of donor organ transport devices that address the current donor organ shortage by maximizing donor organ utilization, improving donor organ quality and extending donor organ transport throughout the entire United States.
1 The SherpaPak™ Organ Transport product line is protected by
patents, both issued and pending
2 The SherpaPak™ Organ Transport product line has received FDA 510(k) pre-market clearance for both heart and kidney organ storage and transport
3 Dr. Michel is on the faculty of the Ludwig-Maximilians-University of Munich
4 The SherpaPerfusion™ Cardiac Transport System is not approved for sale at this time
5 The SherpaPerfusion™ Cardiac Transport System is protected by patents, both issued and pending
6 ISHLT Guidelines for the Care of Heart Transplant Recipients, Task Force 1: Peri-operative Care of the Heart Transplant Recipient (Aug. 4, 2010)
7 J Heart Lung Transplant 2001; 20(2):212.
8 J Am Coll Cardiol 2004; 43(9):1553-1561.
9 Datamonitor senior cardiovascular analyst Dr. Sergey Ishin. “Cardiac transplantation continues to be the gold standard for the treatment of end-stage heart failure. However, the number of potential transplants far exceeds the number of donors.” http://about.datamonitor.com/media/archives/314
10 Circulation 2010;121:e46-e215
12 Circulation 2011;123(8):933-944
13 Circulation 2007;115(5)